These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7908789)

  • 1. Dopa-responsive dystonia: pathological and biochemical observations in a case.
    Rajput AH; Gibb WR; Zhong XH; Shannak KS; Kish S; Chang LG; Hornykiewicz O
    Ann Neurol; 1994 Apr; 35(4):396-402. PubMed ID: 7908789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Segawa disease (hereditary progressive dystonia with marked diurnal fluctuation-HPD) and abnormalities in pteridin metabolism].
    Segawa M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1322-3. PubMed ID: 9128393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia.
    Furukawa Y; Kapatos G; Haycock JW; Worsley J; Wong H; Kish SJ; Nygaard TG
    Ann Neurol; 2002 May; 51(5):637-41. PubMed ID: 12112113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dopa-responsive dystonia: clinical, genetic, and biochemical studies].
    Furukawa Y
    Rinsho Shinkeigaku; 2006 Jan; 46(1):19-34. PubMed ID: 16541791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice.
    Zeng BY; Heales SJ; Canevari L; Rose S; Jenner P
    Exp Neurol; 2004 Dec; 190(2):515-24. PubMed ID: 15530890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics of dopa-responsive dystonia.
    Ichinose H; Suzuki T; Inagaki H; Ohye T; Nagatsu T
    Biol Chem; 1999 Dec; 380(12):1355-64. PubMed ID: 10661862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dopa-responsive dystonia].
    Furukawa Y
    Rinsho Shinkeigaku; 2006 Nov; 46(11):769-73. PubMed ID: 17432176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is levodopa toxic to human substantia nigra?
    Rajput AH; Fenton Me; Birdi S; Macaulay R
    Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary progressive dystonia with marked diurnal fluctuation.
    Segawa M
    Brain Dev; 2011 Mar; 33(3):195-201. PubMed ID: 21094587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
    Collier TJ; Sortwell CE; Elsworth JD; Taylor JR; Roth RH; Sladek JR; Redmond DE
    J Comp Neurol; 2002 Jan; 442(4):320-30. PubMed ID: 11793337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Segawa disease].
    Nomura Y
    Rinsho Shinkeigaku; 1997 Dec; 37(12):1137-8. PubMed ID: 9577670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia.
    Furukawa Y; Nygaard TG; Gütlich M; Rajput AH; Pifl C; DiStefano L; Chang LJ; Price K; Shimadzu M; Hornykiewicz O; Haycock JW; Kish SJ
    Neurology; 1999 Sep; 53(5):1032-41. PubMed ID: 10496263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clue to the pathogenesis of dopa-responsive dystonia.
    Furukawa Y; Mizuno Y; Nishi K; Narabayashi H
    Ann Neurol; 1995 Jan; 37(1):139-40. PubMed ID: 7818251
    [No Abstract]   [Full Text] [Related]  

  • 16. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
    Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
    Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
    Cole DG; Growdon JH; DiFiglia M
    Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new knock-in mouse model of l-DOPA-responsive dystonia.
    Rose SJ; Yu XY; Heinzer AK; Harrast P; Fan X; Raike RS; Thompson VB; Pare JF; Weinshenker D; Smith Y; Jinnah HA; Hess EJ
    Brain; 2015 Oct; 138(Pt 10):2987-3002. PubMed ID: 26220941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
    Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
    Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
    Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.